"JUST PUBLISHED" "Efficacy and Safety of MCNA..." article.......in this past week-end's release of the April-2015, The Journal of Urology. Key excerpts below and link to article at bottom. - Excellent to see and a key catalyst to heighten momentum on all fronts including share price. I will be quite interested and curious how TST uses/leverages this to, in their words..."The Company's primary goal is to develop and commercialize products that advance human health and INCREASE SHAREHOLDER VALUE. (capitalization is my addition). GLTA, rg ----- RESULTS (page 1) - A total of 129 patients were enrolled in study, including 91 with carcinoma in situ with or without papillary disease and 38 with papillary only tumors. Most patients had high risk disease. A total of 107 cases were bacillus Calmette-Guérin refractory and 2 or more prior bacillus Calmette-Guérin induction courses had been given in 68. Median followup in all patients was 34.7 months. The overall disease-free survival rate was 25.0% at 1 year and 19.0% at 2 years. In patients with papillary only tumors the disease-free survival rate was 35.1% and 32.2% at 1 and 2 years, respectively. The median disease-free duration in the 30 responders was 32.7 months. The progression-free survival rate was 87.3%, 79.8% and 77.7% at 1, 2 and 3 years, respectively, with a progression event in 28 patients. MCNA was well tolerated and few adverse events led to treatment discontinuation. CONCLUSIONS (at close of article not abbreviated version on page 1) - Our multicenter study demonstrates the significant activity of intravesical MCNA in patients at high risk in whom BCG failed. In this group, which included BCG refractory and BCG relapsing cases, the overall DFS rate was 25.0% at 1 year and 19.0% at 2 years. When substratified by risk category, MCNA achieved a 39.0% 1-year DFS rate in patients with BCG relapse and 35.1% in patients with papillary tumors. MCNA also achieved a durable response, lower risk of progression events and lower cystectomy rate in responders despite the limited number of patients in each group. Overall MCNA was well tolerated with mostly local AEs of mild or moderate intensity. Thus, while radical cystectomy should still be considered the optimal therapy in these patients, intravesical MCNA provides a safe, effective alternative for those who are not candidates for or who refuse cystectomy. ------ https://ac.els-cdn.com/S002253471404590X/1-s2.0-S002253471404590X-main.pdf?_tid=4586835a-dc57-11e4-9a51-00000aacb35f&acdnat=1428322991_1cdf9b9ada62ec38b4ea0a2771160a74